socalTECH
DECEMBER 27, 2019
Whats happening in regions in our counties with startup and entrepreneurial activity, especially in the Conejo Valley (Calabasas to Thousand Oaks) is exciting. Many jobs have been created and companies have received funding through our efforts of supporting and bringing value to founders. That you cant do it alone.
socalTECH
MAY 20, 2010
The firm, which is headed by Zorik Gordon, was venture backed by VantagePoint Venture Partners, Rho Ventures, Galleon Group, European Founders Fund, and others. The firm's stock was up in its debut despite a down market for the day, with the NASDAQ down -4.11 percent to 2,204.01.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
socalTECH
JUNE 17, 2010
In the latest Southern California firm to target the public markets, Inphi Corp. , Inphi--which lists its headquarters as Sunnyvale, but has most of its operations in Westlake Village and Thousand Oaks--is looking to list on the NYSE and IPHI. In its S-1, the firm said it had net income of $7.3M on total revenues of $58.8M
socalTECH
APRIL 29, 2014
How are you funding this project? This is really also funded because of Mike and my other project, the 101 incubator. The concept of the incubator is we''re raising a fund here locally and ten percent is local the other 90 percent on AngelList, and we''ll be locating here in the town of Thousand Oaks.
socalTECH
OCTOBER 29, 2015
in a funding round. I grew up in Thousand Oaks, went to USC, and we met each other way back in the 90's. There's a massive market, and there is no end to the opportunities here to create efficiency and transform things for the better. Brew Johnson: It's exciting to be building this business in LA. So, what is PeerStreet?
Xconomy
JUNE 10, 2016
Guardant is funding a series of trials around the country in people whose genetic or lifestyle profiles put them at high risk of five types of cancer. The results give the company confidence it can expand its tests to screen for early cancer in high-risk people who are otherwise healthy. The full data set has yet to be released.
Xconomy
JULY 22, 2016
Xconomy spoke with CEO Tom Hughes about the decision, which is terrible news for patients with the rare disease Prader-Willi Syndrome; Zafgen had hoped to win FDA approval of beloranib in Prader-Willi, which would have made it the first marketed drug for the disease since human growth hormone over a decade ago.
Expert insights. Personalized for you.
196 
Let's personalize your content